Does RISANKIZUMAB Cause Neoplasm malignant? 24 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 24 reports of Neoplasm malignant have been filed in association with RISANKIZUMAB (Skyrizi). This represents 0.9% of all adverse event reports for RISANKIZUMAB.
24
Reports of Neoplasm malignant with RISANKIZUMAB
0.9%
of all RISANKIZUMAB reports
4
Deaths
5
Hospitalizations
How Dangerous Is Neoplasm malignant From RISANKIZUMAB?
Of the 24 reports, 4 (16.7%) resulted in death, 5 (20.8%) required hospitalization.
Is Neoplasm malignant Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RISANKIZUMAB. However, 24 reports have been filed with the FAERS database.
What Other Side Effects Does RISANKIZUMAB Cause?
Product storage error (396)
Drug ineffective (206)
Psoriasis (138)
Crohn's disease (103)
Arthralgia (100)
Off label use (100)
Product temperature excursion issue (88)
Diarrhoea (72)
Fatigue (70)
Rash (64)
What Other Drugs Cause Neoplasm malignant?
RANITIDINE (10,648)
ADALIMUMAB (2,028)
APIXABAN (1,772)
ETANERCEPT (1,616)
METHOTREXATE (1,041)
TOFACITINIB (1,020)
RITUXIMAB (929)
INFLIXIMAB (892)
ABATACEPT (727)
RISANKIZUMAB-RZAA (715)
Which RISANKIZUMAB Alternatives Have Lower Neoplasm malignant Risk?
RISANKIZUMAB vs RISANKIZUMAB-RZAA
RISANKIZUMAB vs RISDIPLAM
RISANKIZUMAB vs RISEDRONATE
RISANKIZUMAB vs RISEDRONIC ACID
RISANKIZUMAB vs RISPERDAL